NASDAQ:SYRS - Nasdaq - US87184Q2066 - Common Stock - Currency: USD
Syros Pharmaceuticals stock is down on Tuesday as SYRS investors react to the company discontinuing enrollment for a clinical trial.
SYRS stock results show that Syros Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or the "Company") (NASDAQ: SYRS). Such...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or the "Company") (NASDAQ: SYRS). Such...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or the "Company") (NASDAQ: SYRS). Such...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or the "Company") (NASDAQ: SYRS). Such...
/PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Syros Pharmaceuticals,...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or the "Company") (NASDAQ: SYRS). Such...
/PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Syros Pharmaceuticals,...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or the "Company") (NASDAQ: SYRS). Such...
It's time to dive into the biggest pre-market stock movers for Tuesday as we check out all of the hottest news moving shares this morning.